Last reviewed · How we verify

NCT06910254: oRAGT-PSS

Effects of Overground Robot-Assisted Gait Training on Stroke-Related Sarcopenia

Completed NA Last updated 14 January 2026
What this trial tests

NA trial testing Overground Robot-Assisted Gait Training (o-RAGT) in Stroke in 53 participants. Completed in 30 November 2025.

Timeline
9 June 2025
Primary endpoint
21 November 2025
30 November 2025

Quick facts

Lead sponsorSahmyook University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment53
Start date9 June 2025
Primary completion21 November 2025
Estimated completion30 November 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Sahmyook University

Who can join

Adults 19 to 80, any sex, with Stroke or Sarcopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-center randomized controlled trial evaluates the effects of combining overground robot-assisted gait training (o-RAGT) with recumbent cycling (RC) compared with RC alone in patients with subacute stroke at risk of sarcopenia. The study examines changes in muscle characteristics (muscle mass and quality), falls efficacy, and physical function following a 4-week intervention. Participants are randomly assigned to receive either combined o-RAGT and RC or RC alone. The findings aim to inform the potential role of overground robot-assisted gait training as an adjunctive intervention in stroke rehabilitation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Sahmyook University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06910254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing